AlphAIalphai — Financial news for AI agents
simplywall.stAUG 243 min read$CELC

How Investors May Respond To Celcuity (CELC) Deepening Losses As Gedatolisib Commercial Plans Advance

Celcuity Inc. (CELC) reported a net loss of $78.86 million in Q2 2026, with first-half losses widening to $131.71 million. The company is advancing gedatolisib and preparing for commercialization, with FDA approval of REVTORPYK in July. Investors focus on whether REVTORPYK revenue can offset increased cash burn. Celcuity projects $817.9 million revenue and $267.5 million earnings by 2029, implying a 77% upside from current prices.

Original reporting
simplywall.st
Published Aug 24, 2026, 9:35 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 25, 2026, 11:25 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
How Investors May Respond To Celcuity (CELC) Deepening Losses As Gedatolisib Commercial Plans Advance — source image
Source · simplywall.st
Decision brief

The 30-second read

$CELCBearishLow
01

Why it matters

The widened loss highlights higher cash burn ahead of product launch, raising short‑term risk.

02

Market read

Earnings miss may trigger modest price pressure; investors will watch commercialization progress.

03

What to watch

Potential reimbursement decisions and payer coverage could mitigate cash‑burn concerns.

Relevance 7/10Novelty 6/10Timing: Q2 2026 earnings release

Background

Celcuity (NASDAQ:CELC) is a clinical‑stage biotech advancing its gedatolisib program.

Company-level read

Ticker impact

$CELCBearishMedium confidence
Context

Q2 2026 net loss of $78.86 million reported, widening loss versus prior year.

Expected impact

potential short‑term downside as investors reassess cash runway.

Evidence & confidence

Earnings miss is new information but scale is modest; market reaction likely limited.

Market effects

Sector

Biotech sector may see heightened scrutiny on cash‑burn metrics.

Regional

US biotech investors may adjust exposure to early‑stage cash‑intensive firms.

Global

Limited; primarily affects niche biotech investors.

Counterpoint

What could challenge this read

If REVTORPYK gains rapid uptake, the loss may be viewed as temporary investment in growth.

Key entities

  • Company
    Celcuity Inc.

    Biotech firm developing gedatolisib and REVTORPYK.

Read at source← All news

Related articles

AUG 20
$CELCMed

Celcuity (CELC) Q2 2026 Earnings Call Transcript

Celcuity (CELC) reported Q2 2026 net loss of $78.9M ($1.44/ share), up from $45.3M last year. Cash reserves total $754M, with $557.2M raised from a convertible note offering. The company launched Revtopik, a drug for advanced breast cancer, and plans a supplemental New Drug Application. Clinical trials showed significant reduction in disease progression risk. Management expects cash to fund operations into 2029.

fool.com3 min
AUG 16
$CELCMed

The Bull Case For Celcuity (CELC) Could Change Following Revtopik’s FDA Approval And NCCN Category 1 Status

Celcuity (CELC) reported a wider Q2 net loss of $78.86 million and higher basic loss per share in August 2026. The company said Revtopik received FDA approval and a preferred Category 1 NCCN guideline recommendation for HR-positive, HER2-negative advanced breast cancer, which it says could affect its commercialization outlook. The article cites 2029 revenue of $817.9 million and earnings of $267.5 million.

simplywall.st6 min
AUG 15
$CELCMed

Celcuity Q2 Earnings Call Highlights

Celcuity (NASDAQ:CELC) reported Q2 earnings call highlights for its gedatolisib programs. In REVTORPYK, adverse-event discontinuations were 5.2% (mutant cohort) for the triplet and 3.8% for the doublet, versus 19% for alpelisib. The company is expanding VIKTORIA-2 and advancing a prostate Phase Ib/II trial with darolutamide. Q2 net loss was $78.9M ($1.44/share). Cash totaled $754M.

yahoo.com5 min
AUG 13
$CELCMedAI 8/10

Celcuity Inc. (CELC): Results of Operations and Financial Condition

Celcuity Inc. (CELC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 celc-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update • REVTORPYK™ (gedatolisib) approved by the U.S. FDA for the treatment of HR+/HER2- PIK3CA Wild-Type locally advanced or meta

SEC EDGAR 8-K7 min
AUG 1
$CELCMed

Newly FDA-approved Revtorpyk wins NCCN listing

Celcuity (NASDAQ: CELC) said its Revtorpyk (gedatolisib) plus fulvestrant, with or without palbociclib, was added to NCCN Guidelines as a preferred Category 1 option for HR+, HER2- advanced or metastatic breast cancer after endocrine therapy progression. FDA approved Revtorpyk on July 14, 2026 for HR+/HER2- disease without detected PIK3CA mutation.

thepharmaletter.com4 min